Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Friday, May 12th. They presently have a $7.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 273.33% from the stock’s current price.
A number of other brokerages also recently issued reports on ITEK. Zacks Investment Research raised Inotek Pharmaceuticals Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, January 17th. Canaccord Genuity set a $3.00 target price on Inotek Pharmaceuticals Corporation and gave the stock a “buy” rating in a research note on Thursday, March 16th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Inotek Pharmaceuticals Corporation currently has a consensus rating of “Buy” and a consensus target price of $5.75.
Shares of Inotek Pharmaceuticals Corporation (NASDAQ ITEK) traded down 2.597% during trading on Friday, reaching $1.875. 401,967 shares of the company were exchanged. Inotek Pharmaceuticals Corporation has a 1-year low of $1.50 and a 1-year high of $9.90. The firm’s market capitalization is $50.60 million. The firm’s 50 day moving average is $1.80 and its 200 day moving average is $2.59.
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) last announced its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.01. On average, equities analysts anticipate that Inotek Pharmaceuticals Corporation will post ($1.70) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “HC Wainwright Reiterates “Buy” Rating for Inotek Pharmaceuticals Corporation (ITEK)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.com-unik.info/2017/06/17/inotek-pharmaceuticals-corp-itek-receives-buy-rating-from-hc-wainwright-updated-updated-updated.html.
Institutional investors have recently added to or reduced their stakes in the stock. Putnam Investments LLC increased its position in Inotek Pharmaceuticals Corporation by 1.3% in the fourth quarter. Putnam Investments LLC now owns 34,520 shares of the biotechnology company’s stock valued at $211,000 after buying an additional 447 shares during the last quarter. Morgan Stanley increased its position in Inotek Pharmaceuticals Corporation by 13.1% in the first quarter. Morgan Stanley now owns 67,432 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 7,813 shares during the last quarter. State Street Corp increased its position in Inotek Pharmaceuticals Corporation by 3.5% in the fourth quarter. State Street Corp now owns 265,532 shares of the biotechnology company’s stock valued at $1,618,000 after buying an additional 8,946 shares during the last quarter. Wells Fargo & Company MN bought a new position in Inotek Pharmaceuticals Corporation during the third quarter valued at $101,000. Finally, Trexquant Investment LP bought a new position in Inotek Pharmaceuticals Corporation during the fourth quarter valued at $145,000. 39.48% of the stock is owned by hedge funds and other institutional investors.
About Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
What are top analysts saying about Inotek Pharmaceuticals Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Inotek Pharmaceuticals Corporation and related companies.